News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
327,500 Results
Type
Article (19580)
Company Profile (139)
Press Release (307781)
Section
Business (105173)
Career Advice (867)
Deals (18489)
Drug Delivery (90)
Drug Development (50619)
Employer Resources (79)
FDA (7630)
Job Trends (7716)
News (185470)
Policy (17290)
Tag
Academia (726)
Alliances (27687)
Alzheimer's disease (561)
Approvals (7598)
Artificial intelligence (81)
Bankruptcy (170)
Best Places to Work (5506)
Biosimilars (67)
Biotechnology (62)
Cancer (545)
Cardiovascular disease (60)
Career advice (704)
Cell therapy (83)
Clinical research (41728)
Collaboration (213)
Compensation (69)
COVID-19 (1073)
C-suite (60)
Data (620)
Diabetes (94)
Diagnostics (1716)
Drug pricing (91)
Earnings (38279)
Employer resources (73)
Events (47576)
Executive appointments (199)
FDA (7891)
Funding (156)
Gene therapy (87)
GLP-1 (485)
Government (1797)
Healthcare (5853)
Infectious disease (1121)
Inflammatory bowel disease (67)
Interviews (114)
IPO (7290)
Job creations (2430)
Job search strategy (645)
Layoffs (252)
Legal (4078)
Lung cancer (96)
Manufacturing (128)
Medical device (1946)
Medtech (1949)
Mergers & acquisitions (11237)
Metabolic disorders (326)
Neuroscience (725)
NextGen Class of 2024 (2347)
Non-profit (902)
Northern California (666)
Obesity (210)
Opinion (174)
Patents (70)
People (32898)
Pharmaceutical (75)
Phase I (13000)
Phase II (17662)
Phase III (14222)
Pipeline (283)
Podcasts (56)
Policy (70)
Postmarket research (1610)
Preclinical (4563)
Radiopharmaceuticals (156)
Rare diseases (138)
Real estate (3164)
Regulatory (12118)
Research institute (816)
Resumes & cover letters (138)
Southern California (615)
Startups (2005)
United States (6121)
Vaccines (211)
Weight loss (184)
Date
Today (43)
Last 7 days (328)
Last 30 days (1816)
Last 365 days (17945)
2024 (16425)
2023 (19636)
2022 (25865)
2021 (26639)
2020 (24871)
2019 (20058)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (406)
Asia (24451)
Australia (3147)
California (1498)
Canada (747)
China (147)
Colorado (64)
Connecticut (60)
Europe (50454)
Florida (212)
Illinois (146)
Indiana (115)
Japan (56)
Maryland (228)
Massachusetts (1266)
Minnesota (88)
New Jersey (580)
New York (439)
North Carolina (357)
Northern California (666)
Ohio (63)
Pennsylvania (371)
South America (603)
Southern California (615)
Texas (197)
Washington State (145)
327,500 Results for "cinrx pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
CinRx Pharma Announces Additional $73 Million Financing
CinRx Pharma today announced the closing of a $73 million financing, bringing the total funds raised to $176 million.
May 30, 2024
·
4 min read
Drug Development
CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D)
CinPhloro Pharma, a CinRx Portfolio Company, Dosed First Participant in Phase 2 enviva Study of CIN-103 for Irritable Bowel Syndrome with Predominant Diarrhea (IBS-D).
February 22, 2024
·
3 min read
BioMidwest
CinFina Pharma, a CinRx Portfolio Company, Introduces Scientific Advisory Board with Deep Metabolic Expertise
CinFina Pharma, CinRx Pharma’s portfolio company dedicated to expanding treatment options for obesity and metabolic diseases, announced the scientific advisory board members for the company’s multi-asset pipeline.
December 14, 2023
·
5 min read
BioMidwest
CinDome Pharma Announces $40 Million Series B Extension
CinDome Pharma, a CinRx portfolio company dedicated to advancing a safe, chronic therapy for gastroparesis, today announced a $40 million Series B financing extension.
May 16, 2024
·
3 min read
BioMidwest
CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
CinRx’s CinDome Pharma to Present a Poster on Deudomperidone (CIN-102) at 2023 Digestive Disease Week ® Conference.
May 2, 2023
·
3 min read
Drug Development
CinRx Pharma Announces First Participant Dosed in CinDome’s Phase 2 Study of Deudomperidone (CIN-102) for the Treatment of Diabetic Gastroparesis
CinRx Pharma today announced that the first study participant has been dosed in CinDome Pharma’s Phase 2 envision3D study of deudomperidone (CIN-102) in patients with diabetic gastroparesis.
April 27, 2023
·
4 min read
BioMidwest
CinRx Portfolio Company CinDome Pharma Presents Encouraging Data on Deudomperidone (CIN-102) at 2023 Digestive Disease Week® Conference
CinDome Pharma, a CinRx portfolio company, presented a poster at the 2023 Digestive Disease Week Conference titled “Effect of Therapeutic and Supratherapeutic Doses of Deudomperidone on Cardiac Repolarization in a Thorough QT Study in Healthy Subjects.”
May 8, 2023
·
4 min read
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
Drug Development
CinFina Pharma Announces FDA Clearance of Investigational New Drug Application and First Participants Dosed in Phase 1 Trial of CIN-110 for the Treatment of Obesity
CinFina Pharma, a CinRx portfolio company dedicated to advancing a portfolio of high-impact treatment options for obesity and metabolic diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug Application (IND) for CIN-110, a PYY3-36 analog, allowing the first in-human clinical study to proceed.
March 26, 2024
·
4 min read
News
CinFina Pharma to Present Posters Demonstrating the Potential of New Mechanisms at ObesityWeek® 2024
October 23, 2024
·
2 min read
1 of 32,750
Next